star0602
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2022 (NCT05592626)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Abdominal Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma · Phase 1/Phase 2
- Epstein-Barr Virus Infections · Phase 1/Phase 2
- Genital Neoplasms, Female · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Neoplasms by Site · Phase 1/Phase 2
- Papillomavirus Infections · Phase 1/Phase 2
- Urogenital Neoplasms · Phase 1/Phase 2
- Vulvar Diseases · Phase 1/Phase 2
- Vulvar Neoplasms · Phase 1/Phase 2
Mechanism of action
CD3E activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06827613 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2025 | Marengo Therapeutics, Inc. |
| NCT05592626 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2022 | Marengo Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Marengo Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2022 |
1 organizations
Page 1 / 1